Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1969 1
1970 1
1971 1
1972 3
1974 1
1978 1
1979 3
1980 2
1982 5
1983 4
1984 1
1985 4
1987 3
1988 1
1989 2
1990 5
1991 3
1992 4
1993 1
1994 4
1995 5
1996 5
1997 3
1998 4
1999 6
2000 6
2001 9
2002 8
2003 9
2004 14
2005 10
2006 17
2007 18
2008 30
2009 22
2010 20
2011 30
2012 20
2013 27
2014 21
2015 36
2016 32
2017 26
2018 27
2019 24
2020 32
2021 51
2022 44
2023 49
2024 54
2025 54

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

672 results

Results by year

Filters applied: . Clear all
Page 1
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, Szczylik C, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Lin X, Healy CG, Di Santo N, Zohren F, Fizazi K. Agarwal N, et al. Among authors: healy cg. Lancet. 2023 Jul 22;402(10398):291-303. doi: 10.1016/S0140-6736(23)01055-3. Epub 2023 Jun 4. Lancet. 2023. PMID: 37285865 Clinical Trial.
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, Agarwal N. Fizazi K, et al. Among authors: healy cg. Nat Med. 2024 Jan;30(1):257-264. doi: 10.1038/s41591-023-02704-x. Epub 2023 Dec 4. Nat Med. 2024. PMID: 38049622 Free PMC article. Clinical Trial.
Smoking and alcohol by HPV status in head and neck cancer: a Mendelian randomization study.
Thakral A, Lee JJ, Hou T, Hueniken K, Dudding T, Gormley M, Virani S, Olshan A, Diergaarde B, Ness AR, Waterboer T, Smith-Byrne K, Brennan P, Hayes DN, Sanderson E, Brown MC, Huang S, Bratman SV, Spreafico A, De Almeida J, Davies JC, Bierut L, Macfarlane GJ, Lagiou P, Lagiou A, Polesel J, Agudo A, Alemany L, Ahrens W, Healy CM, Conway DI, Nygard M, Canova C, Holcatova I, Richiardi L, Znaor A, Goldstein DP, Hung RJ, Xu W, Liu G, Espin-Garcia O. Thakral A, et al. Among authors: healy cm. Nat Commun. 2024 Sep 7;15(1):7835. doi: 10.1038/s41467-024-51679-x. Nat Commun. 2024. PMID: 39244563 Free PMC article.
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
de Bono JS, Mehra N, Scagliotti GV, Castro E, Dorff T, Stirling A, Stenzl A, Fleming MT, Higano CS, Saad F, Buttigliero C, van Oort IM, Laird AD, Mata M, Chen HC, Healy CG, Czibere A, Fizazi K. de Bono JS, et al. Among authors: healy cg. Lancet Oncol. 2021 Sep;22(9):1250-1264. doi: 10.1016/S1470-2045(21)00376-4. Epub 2021 Aug 10. Lancet Oncol. 2021. PMID: 34388386 Free article. Clinical Trial.
Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial.
Munoz FM, Bond NH, Maccato M, Pinell P, Hammill HA, Swamy GK, Walter EB, Jackson LA, Englund JA, Edwards MS, Healy CM, Petrie CR, Ferreira J, Goll JB, Baker CJ. Munoz FM, et al. Among authors: healy cm. JAMA. 2014 May 7;311(17):1760-9. doi: 10.1001/jama.2014.3633. JAMA. 2014. PMID: 24794369 Free PMC article. Clinical Trial.
Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4.
Chauhan J, Grandits M, Palhares LCGF, Mele S, Nakamura M, López-Abente J, Crescioli S, Laddach R, Romero-Clavijo P, Cheung A, Stavraka C, Chenoweth AM, Sow HS, Chiaruttini G, Gilbert AE, Dodev T, Koers A, Pellizzari G, Ilieva KM, Man F, Ali N, Hobbs C, Lombardi S, Lionarons DA, Gould HJ, Beavil AJ, Geh JLC, MacKenzie Ross AD, Healy C, Calonje E, Downward J, Nestle FO, Tsoka S, Josephs DH, Blower PJ, Karagiannis P, Lacy KE, Spicer J, Karagiannis SN, Bax HJ. Chauhan J, et al. Among authors: healy c. Nat Commun. 2023 Apr 25;14(1):2192. doi: 10.1038/s41467-023-37811-3. Nat Commun. 2023. PMID: 37185332 Free PMC article.
B cell profiles, antibody repertoire and reactivity reveal dysregulated responses with autoimmune features in melanoma.
Crescioli S, Correa I, Ng J, Willsmore ZN, Laddach R, Chenoweth A, Chauhan J, Di Meo A, Stewart A, Kalliolia E, Alberts E, Adams R, Harris RJ, Mele S, Pellizzari G, Black ABM, Bax HJ, Cheung A, Nakamura M, Hoffmann RM, Terranova-Barberio M, Ali N, Batruch I, Soosaipillai A, Prassas I, Ulndreaj A, Chatanaka MK, Nuamah R, Kannambath S, Dhami P, Geh JLC, MacKenzie Ross AD, Healy C, Grigoriadis A, Kipling D, Karagiannis P, Dunn-Walters DK, Diamandis EP, Tsoka S, Spicer J, Lacy KE, Fraternali F, Karagiannis SN. Crescioli S, et al. Among authors: healy c. Nat Commun. 2023 Jun 8;14(1):3378. doi: 10.1038/s41467-023-39042-y. Nat Commun. 2023. PMID: 37291228 Free PMC article.
672 results